ERBB2 and gastric cancer: Zr-89 trastuzumab PET also enabled monitoring the antitumor activity of a tyrosine kinase inhibitor in HER2-positive gastric cancer models, in which F-18 FDG PET failed to demonstrate the effect of treatment [13].